CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Violet Therapeutics Announces .75M Seed Extension for Neurodegenerative Drug Development

From SV Health Investors

May 17, 2026

Violet Therapeutics Announces .75M Seed Extension for Neurodegenerative Drug Development

Violet Therapeutics Announces .75M Seed Extension for Neurodegenerative Drug Development
Violet Therapeutics, a portfolio company of SV Health Investors, announced a .75 million seed extension financing to advance its lead program targeting EphB3 for neurodegenerative diseases. The round was led by Lifespan Vision Ventures with participation from the Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. Violet's CONNECT platform maps disease-relevant cell-to-cell signaling interactions to discover novel CNS targets.

View original article on svhealthinvestors.com

Most Recent

Foxconn agrees to acquire a 50% stake in Mitsubishi's automotive components unit for ~$727M; Mitsubishi will provide autonomous tech for Foxconn's EV platforms

Hon Hai Precision Industry Co. is paying ¥115 billion ($727 million) for a 50% stake in Mitsubishi Electric Corp.'s automotive-components unit …

Oct 19, 2026

Pax8 launches 8os to let IT partners govern AI agents and 8bot as a managed AI co-worker

Small business software marketplace Pax8 Inc. today launched 8os, an operating system that lets its information technology service provider partners govern the artificial intelligence agents running inside their customers’ businesses. A second product, 8bot, gives those customers’ employees a manage

Oct 19, 2026

Elon Musk says he'll give a SpaceX share to every child in America next year

The SpaceX boss said Monday that he'll give one of his company shares to every child in the U.S. next year. He didn't say how the share giveaway would happen.

Oct 19, 2026

Khosla Ventures doubles down on Even Healthcare to challenge India’s hospital economics

Even Healthcare reaches a $300 million valuation in a Khosla Ventures-led round as it plans to expand its hospital network in India.

Oct 19, 2026

Similar Posts

Violet Therapeutics Raises .75M Seed Extension

Lifespan Vision Ventures leads .75 million seed extension for Violet Therapeutics, a preclinical biotech developing CNS therapies via the CONNECT platform.

May 17, 2026

Waypoint Bio Launches with $14.5 Million Seed Financing

Today we announced the close of a $14.5 million seed financing, led by Hummingbird Ventures, to turbocharge drug discovery using in vivo spatial pooled screening technology.

Jun 28, 2024

Leal Therapeutics announces $30 million Series A for neuro-metabolic therapies

Leal Therapeutics closed a $30 million Series A led by SV Health Investors' Dementia Discovery Fund to advance LTX-001 and LTX-002.

Aug 26, 2025

Leal Therapeutics announces $45 million financing to advance CNS programs

Leal Therapeutics raised $45 million led by Newpath Partners to push LTX-001 and LTX-002 toward first-in-human trials.

Oct 29, 2024